| [1] |
Emmons C,Hunsicker LG.Muromonab-CD3(Orthoclone OKT3):the first monoclonal antibody approved for therapeutic use[J].Iowa Med,1987,77(2):78-82.
|
| [2] |
Gómez-Mantilla JD, Trocóniz IF, Parra-Guillén Z, et al. Review on modeling anti-antibody responses to monoclonal antibodies[J].J Pharmacokinet Pharmacodyn,2014,41(5):523-536.
|
| [3] |
Buss NA,Henderson SJ,McFarlane M,et al.Monoclonal antibody therapeutics:history and future[J].Curr Opin Pharmacol,2012,12(5):615-622.
|
| [4] |
Wang W,Wang EQ,Balthasar JP.Monoclonal antibody pharmacokinetics and pharmacodynamics[J].Clin Pharmacol Ther,2008,84(5):548-558.
|
| [5] |
Dostalek M,Gardner I,Gurbaxani BM,et al.Pharmacokinetics,pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies[J].Clin Pharmacokinet,2013,52(2):83-124.
|
| [6] |
Richter WF,Bhansali SG,Morris ME.Mechanistic determinants of biotherapeutics absorption following SC administration[J].AAPS J,2012,14(3):559-570.
|
| [7] |
Supersaxo A,Hein WR,Steffen H.Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration[J].Pharm Res,1990,7(2):167-169.
|
| [8] |
Porter CJ,Edwards GA,Charman SA.Lymphatic transport of proteins after s.c.injection:implications of animal model selection[J].Adv Drug Deliver Rev,2001,50(1/2):157-171.
|
| [9] |
Lobo ED,Hansen RJ,Balthasar JP.Antibody pharmacokinetics and pharmacodynamics[J].J Pharm Sci,2004,93(11):2645-2668.
|
| [10] |
Zhao L,Shang EY,Sahajwalla CG.Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development[J].J Pharm Sci,2012,101(12):4367-4382.
|
| [11] |
Yokota T,Milenic DE,Whitlow M,et al.Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms[J].Cancer Res,1992,52(12):3402-3408.
|
| [12] |
Ghetie V,Popov S,Borvak J,et al.Increasing the serum persistence of an IgG fragment by random mutagenesis[J].Nat Biotechnol,1997,15(7):637-640.
|
| [13] |
Dall′Acqua WF,Woods RM,Ward ES,et al.Increasing the affinity of a human IgG1 for the neonatal Fc receptor:biological consequences[J].J Immunol,2002,169(9):5171-5180.
|
| [14] |
Weisman MH,Moreland LW,Furst DE,et al.Efficacy,pharmacokinetic,and safety assessment of adalimumab,a fully human anti-tumor necrosis factor-alpha monoclonal antibody,in adults with rheumatoid arthritis receiving concomitant methotrexate:a pilot study[J].Clin Ther,2003,25(6):1700-1721.
|
| [15] |
Gibiansky L,Gibiansky E.Target-mediated drug disposition model:approximations,identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics[J].Expert Opin Drug Met,2009,5(7):803-812.
|
| [16] |
de Vries MK, Brouwer E, van der Horst-Bruinsma IE, et al.Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation[J].Ann Rheum Dis,2009,68(11):1787-1788.
|
| [17] |
Schellekens H.Immunogenicity of therapeutic proteins:clinical implications and future prospects[J].Clin Ther,2002,24(11):1720-1740.
|
| [18] |
Stephens S,Emtage S,Vetterlein O,et al.Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses[J].Immunology,1995,85(4):668-674.
|
| [19] |
Svenson M,Geborek P,Saxne T,et al.Monitoring patients treated with anti-TNF-alpha biopharmaceuticals:assessing serum infliximab and antiinfliximab antibodies[J].Rheumatology,2007,46(12):1828-1834.
|
| [20] |
Rehlaender BN,Cho MJ.Antibodies as carrier proteins[J].Pharm Res,1998,15(11):1652-1656.
|
| [21] |
Kairemo KJ,Lappalainen AK,Kaapa E,et al.In vivo detection of intervertebral disk injury using a radiolabeled monoclonal antibody against keratan sulfate[J].J Nucl Med,2001,42(3):476-482.
|
| [22] |
Danilov SM,Gavrilyuk VD,Franke FE,et al.Lung uptake of antibodies to endothelial antigens:key determinants of vascular immunotargeting[J].Am J Physiol-Lung C,2001,280(6):L1335-L1347.
|
| [23] |
Levy G.Pharmacologic target-mediated drug disposition[J].Clin Pharmacol Ther,1994,56(3):248-252.
|
| [24] |
Mager DE,Jusko WJ.General pharmacokinetic model for drugs exhibiting target-mediated drug disposition[J].J Pharmacokinet Pharmacodyn,2001,28(6):507-532.
|
| [25] |
Mager DE,Krzyzanski W.Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition[J].Pharm Res,2005,22(10):1589-1596.
|
| [26] |
Gibiansky L,Gibiansky E,Kakkar T,et al.Approximations of the target-mediated drug disposition model and identifiability of model parameters[J].J Pharmacokinet Pharmacodyn,2008,35(5):573-591.
|
| [27] |
Davda JP,Jain M,Batra SK,et al.A physiologically based pharmacokinetic(PBPK)model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs[J].Int Immunopharmacol,2008, 8(3):401-413.
|
| [28] |
Covell DG,Barbet J,Holton OD,et al.Pharmacokinetics of monoclonal immunoglobulin G1,F(ab′)2,and Fab′ in mice[J].Cancer Res,1986,46(8):3969-3978.
|
| [29] |
Baxter LT,Zhu H,Mackensen DG,et al.Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice[J].Cancer Res,1994,54(6):1517-1528.
|
| [30] |
Baxter LT,Zhu H,Mackensen DG,et al.Biodistribution of monoclonal antibodies:scale-up from mouse to human using a physiologically based pharmacokinetic model[J].Cancer Res,1995,55(20):4611-4622.
|
| [31] |
Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamics modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia[J].J Pharm Sci,2003,92(6):1206-1215.
|
| [32] |
Shah DK,Betts AM.Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human[J].J Pharmacokinet Pharmacodyn,2012,39(1):67-86.
|
| [33] |
Fetterly GJ,Aras U,Meholick PD,et al.Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2,total CCL2 and carlumab(CNTO 888)concentration time data[J].J Clin Pharmacol,2013,53(10):1020-1027.
|
| [34] |
Sharma A,Davis CB,Tobia LA,et al.Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4[J].J Pharmacol Exp Ther,2000,293(1):33-41.
|
| [35] |
Ng CM,Joshi A,Dedrick RL,et al.Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis[J].Pharm Res,2005,22(7):1088-1100.
|
| [36] |
Shah DK,Haddish-Berhane N,Betts A.Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model:a case study with brentuximab-vedotin[J].J Pharmacokinet Pharm,2012,39(6):643-659.
|
下载:
